Agilent to acquire digital pathology firm Proscia for up to $270 million
Agilent Technologies announced a definitive agreement to purchase Proscia, a provider of enterprise digital pathology software, for $240 million in cash with an additional $30 million contingent on performance milestones. The deal builds on a prior distribution partnership and is expected to close early in Agilent’s fiscal year 2027. Proscia serves more than 4,000 laboratories and 16 of the top 20 pharmaceutical companies and generated over $18 million in trailing twelve‑month revenue.
Why it matters
The acquisition expands Agilent’s pathology portfolio by adding a recurring‑revenue software platform, potentially enhancing cross‑sell opportunities with its instruments and reagents. Completion of the transaction will increase Agilent’s exposure to the fast‑growing digital pathology market, while the earn‑out component could raise the total consideration to $270 million.
Key facts
- 1Agilent will pay $240 million in cash at closing, with up to $30 million additional based on future performance milestones. finance.yahoo.com
- 2Proscia’s trailing twelve‑month revenue exceeded $18 million. finance.yahoo.com
- 3The transaction is expected to close early in Agilent’s fiscal year 2027. finance.yahoo.com
- 4Proscia serves more than 4,000 laboratories, hospitals and clinics, and 16 of the top 20 pharmaceutical companies. investing.com
- 5Agilent President and CEO Padraig McDonnell said digital pathology is becoming the foundation for pathology data generation and analysis. investing.com
- 6The deal value could rise to $270 million if all performance milestones are met. quasa.io
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.